Login to Your Account

Early Phase III Data Hint at Rituxan Replacement

By Marie Powers
Staff Writer

Friday, February 1, 2013
Genentech Inc., a unit of the Roche Group, could add another agent to its formidable oncology arsenal if initial findings from a Phase III study of lead hematology candidate GA101 (obinutuzumab) are borne out in a three-arm trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription